Canada partners with India-based company to secure more AstraZeneca jabs
Canada's vaccine rollout received a significant boost Friday with the approval of a third COVID-19 inoculation, and Prime Minister Justin Trudeau announced another partnership with an India-based institute that will deliver two million additional doses of the newly authorized jab to Canadians by the spring.
Trudeau spoke on Friday hours after Health Canada announced it had approved a COVID-19 vaccine from AstraZeneca.
The new partnership also means Canada will receive two million doses of the CoviShield vaccine, which is the same as AstraZeneca's product, through an agreement with Mississauga, Ont.'s Verity Pharmaceuticals and the Serum Institute of India.
Trudeau says the first shipment of half a million of CoviShield doses will arrive by March.
Health Canada's chief medical adviser Dr. Supriya Sharma said in a briefing Friday that the CoviShield and AstraZeneca products are "for all intents and purposes" the same vaccine.
The difference is in where they are manufactured, she said, using the analogy of the same recipe made in two different kitchens.
The two million doses of CoviShield are in addition to the 20 million doses Canada already secured with AstraZeneca that will start arriving in the spring.
Trudeau said as vaccinations ramp up across the country, many provinces have expanded the number of health professions able to administer a COVID-19 vaccine, and he asked for dentists, midwives, pharmacy technicians and retired nurses to lend a hand in the rollout.
... Canada has now acquired more doses per citizen than any other country in the world.
FDA panel recommends authorization of Johnson & Johnson single-shot vaccine
A key Food and Drug Administration expert panel recommended the approval of the Johnson & Johnson coronavirus vaccine Friday, paving the way for its likely authorization to come as early as Saturday, which would make it the third vaccine available in the United States.
During the hours-long discussion, Johnson & Johnson scientists argued that the single-shot vaccine was 66 percent effective in protecting against cases of moderate to severe illness in a large, global trial, and 85 percent effective against severe cases.
The panel’s recommendation comes the same week the United States reached yet another grim milestone of 500,000 coronavirus-related deaths, raising experts’ hopes of a faster and more effective inoculation process as virus mutations spread.
Here are some significant developments:
Canada’s health regulator approved the coronavirus vaccine from Oxford University and AstraZeneca on Friday, a potential boost for the country’s sluggish vaccine rollout.
California is anticipating a delivery of 380,300 Johnson & Johnson coronavirus vaccine doses by next week, Gov. Gavin Newsom (D) announced in a news conference Friday.
During a tour of a vaccination facility in Texas on Friday, President Biden urged Americans not to let their guard down in the next few months, claiming “it’s not the time to relax” after touting his efforts to combat the pandemic.
Public health officials have eagerly awaited the arrival of Johnson & Johnson’s vaccine. But supply will continue to limit U.S. inoculation efforts in the near term.
I finally realized why you like the ex President so much. You both have something in common.
Bill Maher Whinny Little Bitch - Trump comment - YouTube
CDC scientist says the U.S. is 'nowhere close' to herd immunity
PUBLISHED FRI, FEB 26 2021 11:54 AM EST
UPDATED FRI, FEB 26 2021 6:27 PM EST
Hannah Miao
@HANNAHMIAO_
SHARE
KEY POINTS
The U.S. is "nowhere close" to achieving herd immunity from Covid, a CDC scientist said Friday.
The proliferation of new, more contagious virus strains requires a higher proportion of the population to get vaccinated.
The outbreak could get worse as immunity decreases over time among vaccinated individuals or those who have recovered from Covid.
Bookmarks